Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
While anti-CEA antibodies have no direct effect on CEA-positive tumors, they can be used to direct potent anti-tumor effects as an antibody-IL-2 fusion protein (immunocytokine, ICK), and at the same time reduce the toxicity of IL-2 as a single agent. Using a fusion protein of humanized anti-CEA with...
Main Authors: | Maciej Kujawski, Mark Sherman, Susanta Hui, Darren Zuro, Wen-Hui Lee, Paul Yazaki, Anakim Sherman, Barbara Szpikowska, Junie Chea, Desiree Lasiewski, Kofi Poku, Harry Li, David Colcher, Jeffrey Wong, John E. Shively |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1724052 |
Similar Items
-
Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
by: Seung E. Cha, et al.
Published: (2021-01-01) -
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
by: Christian Klein, et al.
Published: (2017-03-01) -
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
by: Paul M. Sondel, et al.
Published: (2012-07-01) -
Immunocytokines
by: Katrin L. Gutbrodt, et al.
Published: (2012-05-01) -
Utilizing Immunocytokines for Cancer Therapy
by: Erin Runbeck, et al.
Published: (2021-03-01)